Related Experiment Video
Updated: May 7, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Repeat GammaTile Brachytherapy in the Long-Term Management of Recurrent High-Grade Glioma: A Case Report
Jeff F Zhang1, Michael D Mix2, Anna Shapiro2
1Neurological Surgery, Upstate University Hospital, Syracuse, USA.
Abstract:
Over the past two decades, despite the emergence of various novel therapies for glioblastoma, patient survival outcomes remain poor, particularly in the recurrent stage of the disease. Cesium-131 (Cs-131) brachytherapy presents a promising treatment option for patients with newly diagnosed and recurrent brain neoplasms, enabling the initiation of radiation therapy at the time of tumor resection. This approach eliminates the typical delay in therapy following surgery and the need for multiple return visits for fractionated external beam radiotherapy. This report describes a patient who underwent repeat Cs-131 brachytherapy implantations in the surgical cavity following the resection of a recurrent glioblastoma, achieving a good quality of life and survival of over 36 months.

